BioSpace News Archive

Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced the pricing of an underwritten public offering in the United States of 14,285,715 American Depositary Shares (“ADSs”) representing 14,285,715 ordinary shares at a public offering price of $7.00 per ADS, for total gross proceeds of approximately $100.0 million

Vallon Pharmaceuticals, Inc. announced the pricing of its initial public offering of 2,250,000 shares of its common stock at a public offering price of $8.00 per share, for gross proceeds of $18.0 million, before deducting underwriting discounts, commissions and offering expenses.

Enlivex Therapeutics Ltd. announced that due to demand, the underwriter has agreed to increase the size of the previously announced offering and purchase on a firm commitment basis 2,296,107 ordinary shares, par value NIS 0.40 per share, of the Company at a price to the public of $20.00 per ordinary share, less underwriting discounts and commissions.

Total Revenues of $42.7 Million, up 11% Year-over-Year; Subscription Revenues of $31.4 Million, up 12% Year-over-Year

Hepion Pharmaceuticals, Inc. a clinical stage biopharmaceutical company focused on Artificial Intelligence driven therapeutic drug development for the treatment of non-alcoholic steatohepatitis and liver disease, announced today that management will participate in the BIO CEO & Investor Digital Conference, which is being held February 16 - 18, 2021.

James Priour promoted to Chief Commercial Officer, added to Zymeworks’ Executive Committee John Babcook recognized as Distinguished Fellow

Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of checkpoint antibodies, cell therapies, adjuvants, and vaccines designed to activate immune response to cancers and infections, today announced the appointment of Andy Hurley as its Chief Commercial Officer.